COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey

This study reports on 382 COVID-19 patients having undergone allogeneic ( n  = 236) or autologous ( n  = 146) hematopoietic cell transplantation (HCT) reported to the European Society for Blood and Marrow Transplantation (EBMT) or to the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Leukemia Ročník 35; číslo 10; s. 2885 - 2894
Hlavní autoři: Ljungman, Per, de la Camara, Rafael, Mikulska, Malgorzata, Tridello, Gloria, Aguado, Beatriz, Zahrani, Mohsen Al, Apperley, Jane, Berceanu, Ana, Bofarull, Rodrigo Martino, Calbacho, Maria, Ciceri, Fabio, Lopez-Corral, Lucia, Crippa, Claudia, Fox, Maria Laura, Grassi, Anna, Jimenez, Maria-Jose, Demir, Safiye Koçulu, Kwon, Mi, Llamas, Carlos Vallejo, Lorenzo, José Luis López, Mielke, Stephan, Orchard, Kim, Porras, Rocio Parody, Vallisa, Daniele, Xhaard, Alienor, Knelange, Nina Simone, Cedillo, Angel, Kröger, Nicolaus, Piñana, José Luis, Styczynski, Jan
Médium: Journal Article
Jazyk:angličtina
Vydáno: London Nature Publishing Group UK 01.10.2021
Nature Publishing Group
Témata:
ISSN:0887-6924, 1476-5551, 1476-5551
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:This study reports on 382 COVID-19 patients having undergone allogeneic ( n  = 236) or autologous ( n  = 146) hematopoietic cell transplantation (HCT) reported to the European Society for Blood and Marrow Transplantation (EBMT) or to the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH). The median age was 54.1 years (1.0–80.3) for allogeneic, and 60.6 years (7.7–81.6) for autologous HCT patients. The median time from HCT to COVID-19 was 15.8 months (0.2–292.7) in allogeneic and 24.6 months (−0.9 to 350.3) in autologous recipients. 83.5% developed lower respiratory tract disease and 22.5% were admitted to an ICU. Overall survival at 6 weeks from diagnosis was 77.9% and 72.1% in allogeneic and autologous recipients, respectively. Children had a survival of 93.4%. In multivariate analysis, older age ( p  = 0.02), need for ICU ( p  < 0.0001) and moderate/high immunodeficiency index ( p  = 0.04) increased the risk while better performance status ( p  = 0.001) decreased the risk for mortality. Other factors such as underlying diagnosis, time from HCT, GVHD, or ongoing immunosuppression did not significantly impact overall survival. We conclude that HCT patients are at high risk of developing LRTD, require admission to ICU, and have increased mortality in COVID-19.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0887-6924
1476-5551
1476-5551
DOI:10.1038/s41375-021-01302-5